Last reviewed · How we verify

aprotonin; epsilon aminocaproic acid — Competitive Intelligence Brief

aprotonin; epsilon aminocaproic acid (aprotonin; epsilon aminocaproic acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic agent. Area: Cardiovascular / Surgery.

marketed Antifibrinolytic agent Plasmin, kallikrein, plasminogen activators Cardiovascular / Surgery Small molecule Live · refreshed every 30 min

Target snapshot

aprotonin; epsilon aminocaproic acid (aprotonin; epsilon aminocaproic acid) — University of Rochester. This combination inhibits fibrinolysis by blocking plasmin-mediated clot breakdown, thereby reducing bleeding during and after surgery.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
aprotonin; epsilon aminocaproic acid TARGET aprotonin; epsilon aminocaproic acid University of Rochester marketed Antifibrinolytic agent Plasmin, kallikrein, plasminogen activators
Trasylol APROTININ Bayer marketed Antifibrinolytic Agent Plasminogen 1993-01-01
Cyklokapron TRANEXAMIC ACID Exela Pharma marketed Antifibrinolytic Agent [EPC] Plasminogen 1986-01-01
Amicar AMINOCAPROIC ACID Epic Pharma Llc marketed Antifibrinolytic Agent [EPC] Plasminogen 1964-01-01
Tranexamic Acid Injectable Solution Tranexamic Acid Injectable Solution Mount Sinai Hospital, Canada marketed Antifibrinolytic agent Plasminogen / Plasmin
Tranexamic Acid Dosage 1 Tranexamic Acid Dosage 1 Chinese Academy of Medical Sciences, Fuwai Hospital marketed Antifibrinolytic agent Plasminogen / Plasmin
Tranexamic Acid Irrigation Tranexamic Acid Irrigation University of Wisconsin, Madison marketed Antifibrinolytic agent Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic agent class)

  1. Montefiore Medical Center · 2 drugs in this class
  2. Pfizer · 2 drugs in this class
  3. Hamilton Health Sciences Corporation · 2 drugs in this class
  4. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
  5. Henry Ford Health System · 1 drug in this class
  6. Massachusetts General Hospital · 1 drug in this class
  7. NYU Langone Health · 1 drug in this class
  8. Mount Sinai Hospital, Canada · 1 drug in this class
  9. Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 drug in this class
  10. Carlos A Acosta-Olivo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aprotonin; epsilon aminocaproic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/aprotonin-epsilon-aminocaproic-acid. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: